

Additional file 1 – summary of literature search methods

Selected countries	Austria France Germany Hungary Italy Spain Sweden UK
Limits	General literature search: 2010 – Current
Publication types	Case studies Published literature reviews Published guidelines/recommendations Published reports Interview transcripts White papers Research articles
Global electronic databases	Embase, MEDLINE
General websites	ISPOR/ ASCO/ ESMO/ SMDM/ iHEA WHO HTAi OECD

	<p>EFPIA</p> <p>DG SANCO</p> <p>European Commission</p> <p>ONCOTYROL</p> <p>CANCERGEN</p> <p>PHARMGKB</p> <p>EMA</p> <p>Patient and Clinician Engagement group (PACE)</p> <p>European Hospital Association</p>
Country specific websites	<p>NICE/ NHS/ NATIONAL CANCER FUND (UK)</p> <p>HAS/ CEPS/ ANSM/ INCa (France)</p> <p>IQWiG/ DIMDI/ G-BA (Germany)</p> <p>AIFA (Italy; plus regional websites)</p> <p>AETS (Spain; plus regional websites)</p> <p>SBU (Sweden)</p> <p>LBI-HTA (Austria)</p> <p>Austrian Social insurance (www.sozialversicherung.at)</p> <p>NHIF (Hungary)</p> <p>SMC (Scotland)</p> <p>ZINL (Netherlands)</p>
Search Terms	<p>Personalized Medicine/Care</p> <p>Individualised Medicine</p> <p>Stratified Medicine</p>

	<p>Segmented Medicine</p> <p>Targeted Therapies</p> <p>Any of the above with:</p> <ul style="list-style-type: none">+ definition+ individualised/stratified/specialised/segmented/integrated+ genomics/proteomics/metabolomics+ behavioural/psycho-social/social/individual needs+ oncology/cancer/tumours/neoplasm+ technology/diagnostics+ health care/pharmaceuticals+ Europe/France/Italy (including regions)/Germany/Spain (including regions)/ UK/England/ Austria/ Sweden/ Hungary+ expectations+stakeholders/payers/providers/clinical/patients/public/consumer /patient satisfaction+ pharmaceutical + medical devices/products/devices/treatment/novel/innovative/companion diagnostics+ outcomes+ ethics/ethical+ Challenges+ Patient's Preferences
--	--

	<p>+ Economic Models</p> <p>+ Health Technology</p> <p>Assessment/HTA/Funding/Pricing/Reimbursement</p> <p>Companion Diagnostics</p> <p>Challenges</p>
<p>Criteria for inclusion in the review – topics discussed</p>	<p>Definition of personalized medicine</p> <p>Predominant components of personalized medicine</p> <p>Methods for patient segmentation, and current best practices</p> <p>Current HTA, reimbursement, pricing and funding processes for personalized medicine, and impact of these on patient access</p> <p>Specific tools or methods used to inform investment decisions surrounding personalized medicine</p> <p>Challenges to the implementation of personalized medicine</p>

AETS, Agencia de Evaluación de Tecnologías Sanitarias; AIFA, Agenzia Italiana del Farmaco; ANSM, Agence nationale de sécurité du médicament et des produits de santé; ASCO, American Society of Clinical Oncology; CANCERGEN, Cancer Genetics Network; CEPS, Comité Économique des Produits de Santé; DG SANCO, European Commission Directorate General for Health and Consumer Protection; DIMDI, German Institute of Medical Documentation and Information; EFPIA, European Federation of Pharmaceutical Industries and Associations; EMA, European Medicines Association; ESMO, European Society for Medical Oncology; G-BA, Gemeinsamer BundesAusschuss; HAS, Haute Autorité de santé; HTA, Health Technology Assessment; HTAi, Health Technology Assessment international; iHEA, International Health Economics Association; INCA, French National Cancer Institute; IQWiG, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen; ISPOR, International Society for

Pharmacoeconomic and Outcomes Research; LBI-HTA, Ludwig Boltzmann Institute for Health Technology Assessment; NHIF, National Health Insurance Fund; NHS, National Health Service (UK); NICE, National Institute for Health and Care Excellence; ONCOTYROL, Center for Personalized Cancer Medicine (Innsbruck, Austria); OECD, Organisation for Economic Co-operation and Development; PACE, Patient and Clinician Engagement group; PHARMGKB, Pharmacogenomics Knowledgebase; SBU, Swedish Agency for Health Technology Assessment and Assessment of Social Services; SMC, Scottish Medicines Consortium; SMDM, Society for Medical Decision Making; WHO, World Health Organization; ZINL, Zorginstituut Nederland.

PRISMA diagram of publications identified in literature search



